Utilization of Matrix Metalloproteinase-9 Point-of-Care Immunoassay for Meibomian Gland Dysfunction Evaluation in Glaucoma Patients.

Published 04/07/2026

Research record: Utilization of Matrix Metalloproteinase-9 Point-of-Care Immunoassay for Meibomian Gland Dysfunction Evaluation in Glaucoma Patients.

Published in J Clin Med; first publication date 2026-04-07. PMID 41977081.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-04-07

Updated

2026-10-20

Disclaimer

professional use

References